Human papillomavirus type 18 early protein 6 messenger RNA (HPV18 E6 mRNA)

Human papillomavirus type 18 early protein 6 (HPV18 E6) mRNA is a critical viral transcript responsible for the synthesis of the E6 oncoprotein, a primary driver of HPV-mediated oncogenesis. HPV18 is one of the most prevalent high-risk HPV types, frequently associated with adenocarcinoma of the cervix and other mucosal cancers. The E6 protein encoded by this mRNA facilitates the ubiquitination and subsequent proteasomal degradation of the p53 tumor suppressor protein through its interaction with the E6-associated protein (E6AP) (Source: UniProt P06463, NIH/NCI). This loss of p53 function leads to the evasion of apoptosis and uncontrolled cellular proliferation. As a therapeutic target, HPV18 E6 mRNA is approached using nucleic acid-based technologies such as siRNA and antisense oligonucleotides designed to silence the expression of the oncoprotein. Successfully targeting this mRNA can restore cellular checkpoints and induce senescence or death in cancerous cells, making it a high-priority focus for precision oncology in HPV-related malignancies (Source: PubMed PMID: 31434155).

Other names

HPV-18 E6 mRNAHuman papillomavirus 18 E6 transcriptHPV18 E6 oncoprotein mRNA

Therapeutic strategies targeting HPV18 E6 mRNA primarily utilize RNA interference (RNAi) or antisense oligonucleotides (ASOs) to induce sequence-specific degradation of the transcript. By preventing the translation of the E6 oncoprotein, these agents restore the stability of the p53 tumor suppressor protein, thereby promoting apoptosis and cell cycle arrest in HPV-transformed malignant cells (Source: PubMed PMID: 28633215, NIH/NCI).